Cerebral organic acid disorders and other disorders of lysine catabolism

Inborn Metabolic Diseases: Diagnosis and Treatment

Volumn , Issue , 2012, Pages 333-347

  Hoffmann, Georg F ^a   Kolker, Stefan ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876281615     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-15720-2_23     Document Type: Chapter

References (61)

1. Hoffmann GF, Gibson KM, Trefz FK et al. (1994) Neurological manifestations of organic acid disorders. Eur J Pediatr 153 [Suppl 1]:S94-100
2. Dancis J, Hutzler J, Ampola MG et al. (1983) The prognosis of hyperlysinemia: an interim report. Am J Hum Genet 35:438-442
3. Sacksteder KA, Biery BJ, Morell JC et al. (2000) identification of the α-aminoadipic semialdehyde synthase gene, which is defective in familial hyperlysinemia. Am J Hum Genet 66:1736-1743
4. Przyrembel H (2002) Disorders of ornithine, lysine and tryptophan. In: Blau N, Duran Blaskovics M, Gibson KM (eds) Physician’s guide to the laboratory diagnosis of inherited metabolic disease. Chapman & Hall, London, pp 277-300
5. Saudubray JM, Rabier D (2007) Biomarkers identified in inborn errors of lysine, arginine and ornithine. J Nutr 137:1669S-1672S
6. Goodman SI, Browder JA, Hiles RA, Miles BS (1972) Hydroxylysinemia. A disorder due to a defect in the metabolism of free hydroxylysin. Biochem Med 6:344-354
7. Przyrembel H, Bachmann D, Lombeck I et al. (1975) Alphaketoadipic aciduria, a new inborn error of lysine metabolism; biochemical studies. Clin Chim Acta 58:257-269
8. Kyllerman M, Skjeldal O, Christensen E et al. (2004) Long-term follow-up, neurological outcome and survival rate in 28 Nordic patients with glutaric aciduria type 1. Eur J Paediatr Neurol 8:121-129
9. Strauss KA, Puffenberger EG, Robinson DL, Morton DH (2003) Type I glutaric aciduria, part 1: natural history of 77 patients. Am J Med Genet 121C:38-52
10. Kolker S, Garbade SF, Greenberg CR et al. (2006) Natural history, outcome and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency. Pediatr Res 59:840-847
11. Gitiaux C, Roze E, Kinugawa K et al. (2008) Spectrum of movement disorders associated with glutaric aciduria type 1: a study of 16 patients. Mov Disord 23:2392-2397
12. Harting I, Neumaier-Probst E, Seitz A et al. (2009) Dynamic changes of striatal and extrastriatal abnormalities in glutaric aciduria type I. Brain 132:1764-1782
13. Morris AAM, Hoffmann GF, Naughten ER et al. (1999) Glutaric aciduria and suspected child abuse. Arch Dis Childh 80:404-405
14. Strauss KA, Donelly P, Wintermark M (2010) Cerebral haemodynamics in patients with glutaryl-coenzmye A dehydrogenase deficiency. Brain 133:76-92
15. Heringer J, Boy SPN, Ensenauer R et al. (2010) Use of guidelines improves the outcome in glutaric aciduria type I. Ann Neurol 68:743-752
16. Kolker S, Koeller DM, Okun JG, Hoffmann GF (2004) Pathomechanisms of neurodegeneration in glutaryl-CoA dehydrogenase deficiency. Ann Neurol 55:7-12
17. Sauer SW, Okun JG, Schwab MA et al. (2005) Bioenergetics in glutaryl- coenzyme A dehydrogenase deficiency: a role for glutarylcoenzyme A. J Biol Chem 280:2180-21836
18. Sauer SW, Okun JG, Fricker G et al. (2006) Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood-brain barrier constitutes a biochemical risk factor for neurodegeneration in glutaryl-CoA dehydrogenase deficiency. J Neurochem 97:899-910
19. Stellmer F, Keyser B, Burckhardt BC et al. (2007) 3-Hydroxyglutaric acid is transported via the sodium-dependent dicarboxylate transporter NaDC3. J Mol Med 85:763-770
20. Goodman SI, Stein DE, Schlesinger S et al. (1998) Glutaryl-CoA dehydrogenase mutations in glutaric acidemia (type I): Review and report of thirty novel mutations. Hum Mutat 12:141-144
21. Baric I, Wagner L, Feyh P, Liesert M, Buckel W, Hoffmann GF (1999) Sensitivity and specificity of free and total glutaric and 3-hydroxyglutaric acids measurements by stable isotope dilution assays for the diagnosis of glutaric aciduria type I. J Inherit Metab Dis 22:867-882
22. Lindner M, Kolker S, Schulze A et al. (2004) Neonatal screening for glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 27:851-859
23. Christensen E (1993) A fibroblast glutaryl-CoA dehydrogenase assay using detritiation of 3H-labelled glutaryl-CoA: application in the genotyping of the glutaryl-CoA dehydrogenas locus. Clin Chim Acta 220:71-80
24. Kolker S, Christensen E, Leonard JV et al. (2007) Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I). J Inherit Metab Dis 30:5-22
25. Kolker S, Garbade SF, Boy N et al. (2007) Decline of acute encephalopathic crises in children with glutaryl-CoA dehydrogenase deficiency identified by newborn screening in Germany. Pediatr Res 62:357-363
26. Strauss KA, Lazovic J, Wintermark M et al. (2007) Multimodal imaging of striatal degeneration in Amish patients with glutaryl- CoA dehydrogenase deficiency. Brain 130:1905-1920
27. Monavari AA, Naughten ER (2000) Prevention of cerebral palsy in glutaric aciduria type 1 by dietary management. Arch Dis Chil 82:67-70
28. Knerr I, Zschocke J, Trautmann U et al. (2002) Glutaric aciduria type III: a distinctive non-disease. J Inherit Metab Dis 25:483- 490
29. Sherman EA, Strauss KA, Tortorelli S et al. (2008) Genetic mapping of glutaric aciduria, type 3, to chromosome 7 and identification of mutations in C7orf10. Am J Hum Genet 83:604-609
30. Barth PG, Hoffmann GF, Jaeken J et al. (1993) L-2-Hydroxyglutaric acidemia: clinical and biochemical findings in 12 patients and preliminary report on L-2-hydroxyacid dehydrogenase. J Inherit Metab Dis 16:753-761
31. Moroni I, D’Incerti L, Farina L et al. (2000) Clinical, biochemical and neuroradiological findings in L-2-hydroxyglutaric aciduria. Neurol Sci 21:103-108
32. Chen E, Nyhan WL, Jakobs C et al. (1996) L-2-Hydroxyglutaric aciduria: neuropathological correlations and first report of severe neurodegenerative disease and neonatal death. J Inherit Metab Dis 19:335-343
33. Moroni I, Bugiani L, D’Incerti C et al. (2004) L-2-Hydroxyglutaric aciduria and brain malignant tumors: A predisposing condition? Neurology 62:1882-1884
34. Hoffmann GF, Jakobs C, Holmes B et al. (1995) Organic acids in cerebrospinal fluid and plasma of patients with L-2-hydroxyglutaric aciduria. J Inherit Metab Dis 18:189-193
35. Rzem R, Veiga-da-Cunha M, Noel G et al. (2004) A gene encoding a putative FAD-dependent L-2-hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria. Proc Natl Acad Sci U S A 101:16849-16854
36. Rzem R, Vincent MF, Schaftingen v E et al. (2007) L-2-Hydroxyglutaric aciduria, a defect of metabolite repair. J Inherit Metab Dis 30:681-689
37. Topcu M, Jobard F, Halliez S et al. (2004) L-2-Hydroxyglutaric aciduria: identification of a mutant gene C14orf160, localised on chromosome 14q22.1. Hum Mol Genet 13:2803-2811
38. Gibson KM, Schor DSM, Kok RM et al. (1993) Stable-isotope dilution analysis of D- and L-2-hydroxyglutaric acid: application to the detection and prenatal diagnosis of D- and L-2-hydroxyglutaric acidemias. Pediatr Res 34:277-280
39. Samuraki M, Komai K, Hasegawa Y et al. (2008) A successfully treated adult patient with L-2-hydroxyglutaric aciduria. Neurology 70:1051-1052
40. Gibson KM, Craigen W, Herman GE, Jakobs C (1993) D-2-Hydroxyglutaric aciduria in a newborn with neurological abnormalities: a new neurometabolic disorder? J Inherit Metab Dis 16:497-500
41. Knaap v d MS, Jakobs C, Hoffmann GF et al. (1999) D-2-Hydroxyglutaric aciduria. Biochemical marker or clinical disease entity? Ann Neurol 45:111-119
42. Achouri Y, Noel G, Vertommen D et al. (2004) Identification of a dehydrogenase acting on D-2-hydroxyglutarate. Biochem J 381:35-42
43. Struys EA, Salomons GS, Achouri Y et al. (2005) Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. Am J Hum Genet 76:358-360
44. Kranendijk M, Struys EA, Schaftingen v E et al. (2010) IDH2 Mutations in patients with D-2-hydroxyglutaric aciduria. Science 330:336
45. Dang L, White DW, Gross S et al. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739-744
46. Ward PS, Patel J, Wise DR et al. (2010) The common feature of leukemia- associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting a-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:1-10
47. Kranendijk M, Struys EA, Gibson KM et al. (2010) Evidence for genetic heterogeneity in D-2-hydroxyglutaric aciduria. Hum Mut 31:279-283
48. Muntau AC, Roschinger W, Merkenschlager A et al. (2000) Combined D-2 and L-2-hydroxyglutaric aciduria with neonatal onset encephalopathy: A third biochemical variant of 2-hydroxyglutaric aciduria? Neuropediatrics 31:137-140
49. Matalon R, Michals K, Kaul R (1995) Canavan disease: from spongy degeneration to molecular analysis. J Pediatr 127:511-517
50. Brismar J, Brismar G, Gascon G, Ozand P (1990) Canavan disease: CT and MR imaging of the brain. Am J Neuroradiol 11:805-810
51. Madhavarao CN, Arun P, Moffett JR et al. (2005) Defective Nacetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan’s disease. PNAS 102:5221-5226
52. Baslow MH (2002) Evidence supporting a role for N-acetyl-Laspartate as a molecular water pump in myelinated neurons in the central nervous system. An analytical review. Neurochem Int 40:295-300
53. Matalon R, Michals-Matalon K (1998) Molecular basis of Canavan disease. Eur J Paediatr Neurol 2:69-76
54. Howell VM, Proos AL, LaRue D et al. (2004) Carrier screening for Canavan disease in Australia. J Inherit Metab Dis 27:289-290
55. Besley GTN, Elpeleg ON, Shaag A et al. (1999) Prenatal diagnosis of Canavan disease: Problems and dilemmas. J Inherit Metab Dis 22:263-266
56. Assadi M, Janson C, Wan DJ et al. (2010) Lithium citrate reduces excessive intracerebral N-acetylaspartate in Canavan disease. Eur J Paediatr Neurol 14:354-359
57. Madhavarao CN, Arun P, Anikster Y et al. (2009) Glyceryl triacetate for Cananvan disease: A low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model. J Inherit Metab Dis 32:640-650
58. Leone P, Janson CG, Bilanuk L et al. (2000) Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann Neurol 48:27-38
59. McPhee SW, Francis J, Janson CG et al. (2005) Effects of AAV-2- mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease. Brain Res Mol Brain Res 135:112-121
60. Bolthauser E, Schmitt B, Wevers RA et al. (2004) Follow-up of a child with hypoacetylaspartia. Neuropediatrics 35: 255-258
61. Wiame E, Tyteca D, Pierrot N et al. (2010) Molecular identification of aspartate N-acetyltransferase and its mutation in hypoacetylaspartia. Biochem J 425:127-136